Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent

MSN
2025.10.24 11:30
portai
I'm PortAI, I can summarize articles.

Sanofi shares rose slightly after reporting Q3 2025 results that surpassed expectations, driven by strong sales of its asthma drug Dupixent, which generated €4.2B with a 26% YoY growth. Total sales reached €12.4B, exceeding analyst projections. Despite an 8% decline in vaccine sales, Sanofi anticipates high single-digit sales growth and low double-digit EPS growth for 2025. The company is in discussions with U.S. policymakers regarding drug pricing and has expanded its insulin savings program to improve access.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.